Mindfulness-Based Cognitive Therapy + Safety Planning For Suicidal Behavior
|ClinicalTrials.gov Identifier: NCT01826240|
Recruitment Status : Completed
First Posted : April 8, 2013
Last Update Posted : December 4, 2015
|Condition or disease||Intervention/treatment||Phase|
|Monopolar Depression, Single Episode or Unspecified Suicidal and Self-injurious Behaviour||Behavioral: MBCT+SPI||Phase 1|
- The study is a nine-week clinical trial combining Safety Planning Intervention plus Mindfulness-Based Cognitive Therapy for patients with a recent history of suicidal thoughts or behavior and current or past depressive symptoms.
- These treatments work for depression and some preliminary data suggest they may work to prevent suicidal behavior.
- Nine weeks of free treatment
- Clinical assessments
- An opportunity to offer your views on treatment and suggestions for improving the treatment in focus groups
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Mindfulness-Based Cognitive Therapy + Safety Planning For Suicidal Behavior: A Treatment Development Study|
|Study Start Date :||March 2013|
|Actual Primary Completion Date :||February 2015|
|Actual Study Completion Date :||February 2015|
Note: There is only one condition in this study. Mindfulness-Based Cognitive Therapy (MBCT) is combined with Safety Planning Intervention (SPI). All individuals who choose to participate will receive MBCT+SPI.
Safety Planning Intervention (SPI), a very brief intervention focused on identifying personalized coping strategies to manage acute suicidality, is combined with Mindfulness-Based Cognitive Therapy (MBCT), a group intervention comprised of mindfulness training and cognitive therapy techniques. Treatment lasts 9 weeks.
- Retention [ Time Frame: participants will be followed for the duration of treatment, an expected average of 9 weeks ]Feasibility
- Consumer Satisfaction Questionnaire [ Time Frame: post-treatment (at 9 weeks) ]Acceptability
- Change in scores on Scale for Suicide Ideation [ Time Frame: participants will be followed for the duration of treatment, an expected average of 9 weeks ]Safety
- Change in scores on Beck Depression Inventory (BDI-II) [ Time Frame: baseline and post-treatment (at 9 weeks) ]Effectiveness
- Change in cognitive processes underlying treatment gains [ Time Frame: baseline and post-treatment (at 9 weeks) ]neuropsychological tasks assessing attention and other cognitive processes
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01826240
|United States, New York|
|Columbia University/New York State Psychiatric Institute|
|New York, New York, United States, 10032|
|Principal Investigator:||Megan Chesin, Ph.D.||Columbia University|